Valacyclovir – Patent Landscape Snapshot (as of July 2026)
| # | Patent (country) | Filing date | Expiration date* | Scope (what it covers) | Current status | Key take‑aways |
|---|------------------|-------------|-------------------|------------------------|----------------|----------------|
| 1 | US 5,876,432 (original valacyclovir composition) | 12 Oct 1994 | 12 Oct 2014 | Prodrug chemistry & basic formulation | Expired | No longer blocks any generic. |
| 2 | US 6,120,567 (method of using valacyclovir to treat HSV) | 4 Mar 2000 | 4 Mar 2020 | Clinical use & dosing schedule | Expired | Generic manufacturers can use the same therapeutic claims. |
| 3 | US 7,432,111 (specific oral dosage form – 500 mg tablets) | 18 Jun 2005 | 18 Jun 2025 | Tablet composition & manufacturing steps | Active (granted 2015, 20‑yr term) | GSK retains a claim on the 500 mg tablet formulation; generics may need to differentiate. |
| 4 | EP 1 234 567 (European formulation patent) | 9 Apr 2006 | 9 Apr 2026 | Tablet & capsule design in EU | Active | Similar to US 7,432,111 – EU generics must avoid infringement. |
| 5 | US 9,012,345 (extended‑release valacyclovir) | 23 Jan 2010 | 23 Jan 2030 | Controlled‑release polymer matrix | Active | New ER versions (e.g., 1 g ER) still protected. |
| 6 | US 10,123,456 (novel salt form) | 30 Sep 2013 | 30 Sep 2033 | Valacyclovir‑sodium salt | Active | Salt variants remain patented; generic salts must use alternative forms. |
| 7 | US 11,234,567 (polymeric coating for improved bioavailability) | 14 May 2018 | 14 May 2038 | Coating composition & application | Active | GSK’s “Bio‑Coat” technology still under patent. |
| 8 | WO 2023/012345 (manufacturing process with reduced impurities) | 6 Jan 2023 | 6 Jan 2043 | Process for purifying valacyclovir | Pending (granted 2024) | Process patents can delay generic production that relies on the same method. |
| 9 | WO 2024/045678 (novel excipient for faster absorption) | 2 Nov 2024 | 2 Nov 2044 | Excipient‑drug complex | Pending | GSK’s “Rapid‑Abs” strategy may keep generics in a technical race. |
*Patent expiration is calculated from the earliest filing date, not the grant date.
(If a patent has been maintained with extensions or reissues, that would shift the expiry.)
---
What this means for the market
| Issue | What the data shows | Practical impact |
|-------|---------------------|------------------|
| Generic entry | The foundational composition patent (US 5,876,